JP Morgan Chase’s Roivant Sciences ROIV Stock Holding History

JP Morgan Chase’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.2M	Buy	+33,000	New	+$1.2M	﹤0.01%	4654

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return

JP Morgan Chase's ROIV Position: Q3 2026 in Review

JP Morgan Chase increased its Roivant Sciences (ROIV) stake by 630% in Q3 2026, buying an estimated $260M and bringing the position to 8,300,820 shares worth $304M. The position accounts for 0.02% of the portfolio, ranked #608.

JP Morgan Chase first reported a position in ROIV in Q2 2022 and has held it in 18 quarters since. 395 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

JP Morgan Chase held 8,300,820 shares of Roivant Sciences worth $304M as of Q3 2026.
JP Morgan Chase bought 7,162,953 Roivant Sciences shares in Q3 2026, an estimated $260M.
Roivant Sciences made up 0.02% of JP Morgan Chase's portfolio in Q3 2026, its #608 holding.
JP Morgan Chase first reported a position in Roivant Sciences in Q2 2022 and has held it in 18 quarters since.
395 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.